Cardiovascular & Metabolic: Beyond GLP-1 - Novel Mechanisms & Combination
Description
GLP-1 agents expanding cardiovascular indication potential. SGLT2i, GLP-1 combination therapeutic opportunities. Heart failure prevention in non-diabetics. Atherosclerotic CVD optimization. Lipid management innovations.
Table of Contents
70 Pages
- EXECUTIVE SUMMARY
- 1.1 Cardiovascular Market Evolution
- 1.2 GLP-1 Expansion Beyond Diabetes
- 2.0 THERAPEUTIC COMBINATIONS
- 2.1 GLP-1 + SGLT2i
- 2.2 Combination Efficacy
- 2.3 Patient Selection
- 3.0 NOVEL MECHANISMS
- 3.1 Heart Failure Prevention
- 3.2 Atherosclerosis Prevention
- 3.3 Lipid Management
- 4.0 CLINICAL DEVELOPMENT
- 4.1 Outcome Studies Design
- 4.2 Biomarker Strategy
- 4.3 Patient Populations
- 5.0 COMMERCIAL STRATEGY
- 5.1 Indication Expansion
- 5.2 Pricing Strategy
- 5.3 Payer Engagement
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

